Literature DB >> 11045843

Lactose-[13C]ureide breath test: a new, noninvasive technique to determine orocecal transit time in children.

M Van Den Driessche1, N Van Malderen, B Geypens, Y Ghoos, G Veereman-Wauters.   

Abstract

BACKGROUND: The lactose-[13C]ureide breath test (LUBT) is a novel, noninvasive test to determine orocecal transit time. Lactose ureide resists the action of brush border enzymes and is metabolized by colonic bacteria. The purpose of the present study was to adapt this breath test for children of various age groups and to determine whether it can be applied in infants, newborns, and preterms to study the development of small intestinal motility.
METHODS: In a group of 20 children (3-17 years) in vitro stool analysis and in vivo LUBT results were compared. From each subject a blank stool sample and a sample produced after induction with unlabeled lactose ureide were incubated with 10 mg lactose-[13C]ureide in small, closed bottles. Ten-milliliter CO2 samples were aspirated from the bottles using a needle and a syringe every 30 minutes for 24 hours. All children performed the breath test after induction of 500 mg unlabeled lactose ureide three times the prior day. A liquid test meal (chocolate milk) with 250 mg lactose-[13C]ureide was ingested. Breath samples were collected every 15 minutes for 10 hours. In a second group of 32 children (age range, 0-3 years) consisting of 6 children between 1 and 3 years of age, 6 infants between 6 and 12 months, 13 infants between 0 and 6 months, and 7 preterm infants, only the in vitro stool analysis was performed. Stools were collected for stool incubation, as described.
RESULTS: The mean orocecal transit time in the group of 20 children aged 3 to 17 years was 255 minutes (range, 165-390 minutes). Stool incubations demonstrated a clear 13CO2 peak in all infants aged more than 8 months, indicating that their colonic bacterial enzymic activity hydrolyses lactose ureide. However, in all infants aged less than 6 months and in preterm infants, the 13CO2 signal was absent, indicating that those subjects were unable to hydrolyze lactose ureide.
CONCLUSION: Infants aged less than 6 months do not host the appropriate bacterial enzymic activity for splitting lactose ureide. The authors conclude that the LUBT can be applied in infants aged more than 8 months, after weaning to solid foods, to determine orocecal transit time.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045843     DOI: 10.1097/00005176-200010000-00019

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  8 in total

Review 1.  Methods for the assessment of small-bowel and colonic transit.

Authors:  Lawrence A Szarka; Michael Camilleri
Journal:  Semin Nucl Med       Date:  2012-03       Impact factor: 4.446

Review 2.  Protein Digestion of Baby Foods: Study Approaches and Implications for Infant Health.

Authors:  Junai Gan; Gail M Bornhorst; Bethany M Henrick; J Bruce German
Journal:  Mol Nutr Food Res       Date:  2017-10-17       Impact factor: 5.914

3.  Investigating Oral Absorption of Carbamazepine in Pediatric Populations.

Authors:  Philip Kohlmann; Cordula Stillhart; Martin Kuentz; Neil Parrott
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

4.  Use of the lactose-[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test.

Authors:  Heiner K Berthold; Patrick Schober; Christian Scheurlen; Günter Marklein; Regine Horré; Ioanna Gouni-Berthold; Tilman Sauerbruch
Journal:  J Gastroenterol       Date:  2009-06-24       Impact factor: 7.527

5.  Evaluation of the passage of Lactobacillus gasseri K7 and bifidobacteria from the stomach to intestines using a single reactor model.

Authors:  Philipp Ritter; Christian Kohler; Ueli von Ah
Journal:  BMC Microbiol       Date:  2009-05-08       Impact factor: 3.605

Review 6.  European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.

Authors:  Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2021-06-14       Impact factor: 4.623

7.  Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.

Authors:  Stefan Willmann; Corina Becker; Rolf Burghaus; Katrin Coboeken; Andrea Edginton; Jörg Lippert; Hans-Ulrich Siegmund; Kirstin Thelen; Wolfgang Mück
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

8.  A preliminary study of (13)c-phenylalanine and (13)c-dipeptide breath tests in horses.

Authors:  Naoki Sasaki; Nao Tsuzuki; Michiaki Yamada; Takuto Minami; Haruo Yamada
Journal:  J Equine Sci       Date:  2009-04-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.